CPRX Stock Analysis: Buy, Sell, or Hold?
CPRX - Catalyst Pharmaceutical Inc.
$24.30
-0.28 (-1.14%)
▼
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Feb 25, 2026
23d
Get Alerted When CPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CPRX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: CPRX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$27.45
Based on 3.1% avg growth
INTRINSIC VALUE TODAY
$17.04
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CPRX is currently trading at $24.30, which is considered slightly high relative to its 30-day fair value range of $22.79 to $24.07. The stock's valuation (Forward PE: 9.4) is in line with its historical norms (9.1). At these levels, the market is pricing in 1.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CPRX is in a strong uptrend. The price is approaching resistance at $24.83. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CPRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.57 (+42.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CPRX is in a strong uptrend. The price is approaching resistance at $24.83. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CPRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.57 (+42.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$22.79 -
$24.07
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 42.3% below Wall St target ($34.57)
- NEUTRAL: Market pricing in 1.0% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$22.79 -
$24.07
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$22.33
Resistance Level
$24.83
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
9.36
Wall Street Target
$34.57
(+42.3%)
Revenue Growth (YoY)
15.3%
Earnings Growth (YoY)
20.0%
Profit Margin
37.6%
Valuation Premium vs History
+1.0% premium
PE vs Historical
9.4 vs 9.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.0%
(market-implied from PE analysis)
1-Year Target
$24.54
(+1%)
2-Year Target
$24.79
(+2%)
3-Year Target
$25.04
(+3%)
3-Yr Target (if PE normalizes)
(PE: 9→9)
PE COMPRESSION
$24.34
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 2.1%)
$61.64
(+154%)
Base:
(SPY PE: 9.4, Growth: 2.1%)
$25.88
(+7%)
Bear:
(PE: 8.0, Growth: 2.1%)
$22.00
(-10%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 14.15 | Current EPS (TTM): $1.71
Bull Case
$40.28
(+66%)
Analyst growth 51.3%, PE expands to 15.6
Base Case
$36.62
(+51%)
Market implied 51.3%, PE stable at 14.2
Bear Case
$16.46
(-32%)
Severe decline -20.0%, PE contracts to 12.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: February 01, 2026 4:30 PM ET
Data refreshes hourly during market hours. Next update: 5:30 PM
Data refreshes hourly during market hours. Next update: 5:30 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Brian Elsbernd
SELL
30000 shares
2025-09-08
Brian Elsbernd
SELL
30000 shares
2025-09-04
Brian Elsbernd
SELL
20000 shares
2025-09-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 59 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$140 | 59 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$42 | 64 BUY |
